awmsg logo



linaclotide (Constella®)


Reference No. 948

Publication date:
27/02/2014


Appraisal information

linaclotide (Constella®) 290 micrograms capsule


Company: Almirall Ltd
BNF category: Gastro-intestinal system
NMG meeting date: 27/11/2013
AWMSG meeting date: 15/01/2014
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0314
Ministerial ratification: 26/02/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Linaclotide (Constella®) is recommended as an option for restricted use within NHS Wales. Linaclotide (Constella®) should be restricted for use in the following subpopulation within its licensed indication for the symptomatic treatment of moderate to severe irritable bowel syndrome (IBS) with constipation in adults: • Patients who have not responded adequately to or cannot tolerate antispasmodics and/or laxatives. Linaclotide (Constella®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download